Skip to main content

Table 3 Trough infliximab concentration (mg/L) during infliximab initiation for ATIpos and ATIneg patients with RA and SpAa

From: Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

  RA (n= 17) SpA (n= 91)
Time after infliximab initiation ATIpos (n= 7) ATIneg (n= 10) Pvalue ATIpos (n= 14) ATIneg (n= 77) Pvalue
Week 2 7.7 (2.8 to 16.9) 27.2 (7.1 to 41.9) 0.002 25.0 (4.0 to 40.7) 35.8 (14.3 to 57.2) 0.003
Week 6 0.3 (0 to 6.2) 15.4 (2.7 to 35.0) 0.001 11.9 (0 to 24.2) 29.5 (3.4 to 69.0) < 0.001
Weeks 12 and 14 0 (0 to 0.03) 5.4 (0 to 21.9) 0.01 1.6 (0 to 13.5) 15.8 (0.7 to 47.3) < 0.001
  1. aATI: antibodies toward infliximab; ATIpos: ATI detected at least once during follow-up; ATIneg: ATI not detected; RA: rheumatoid arthritis; SpA: spondyloarthritis. Results are given as medians (ranges).